Aby Mathew Sells 529 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 529 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $20.74, for a total transaction of $10,971.46. Following the sale, the executive vice president directly owned 392,937 shares of the company’s stock, valued at approximately $8,149,513.38. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

BioLife Solutions Stock Down 2.7%

Shares of BLFS traded down $0.55 during trading on Thursday, reaching $20.12. The company’s stock had a trading volume of 639,660 shares, compared to its average volume of 408,797. The company has a fifty day moving average of $23.57 and a two-hundred day moving average of $25.13. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The company has a market cap of $971.80 million, a price-to-earnings ratio of -182.89 and a beta of 1.90.

Analysts Set New Price Targets

BLFS has been the subject of a number of research analyst reports. Wall Street Zen upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BLFS. T. Rowe Price Investment Management Inc. increased its holdings in BioLife Solutions by 27.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock valued at $125,273,000 after buying an additional 1,113,972 shares during the last quarter. Invesco Ltd. boosted its stake in BioLife Solutions by 9.2% in the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock worth $95,080,000 after purchasing an additional 332,747 shares during the period. XTX Topco Ltd increased its holdings in BioLife Solutions by 280.4% in the 4th quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider’s stock valued at $877,000 after acquiring an additional 26,729 shares during the last quarter. SummitTX Capital L.P. bought a new stake in BioLife Solutions in the 4th quarter worth approximately $1,747,000. Finally, Sandler Capital Management bought a new position in shares of BioLife Solutions in the 4th quarter valued at about $765,000. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.